Talian Hotline Kami
+603 - 8230 0300
Utama
Pengenalan
Latar Belakang
Visi, Misi & Nilai Teras
Objektif
Carta Organisasi
Kod Etika dan Tatakelakuan
Board of Directors
Top Management Team of MDA
Malaysian Leadership
Former CEO of MDA
Bahagian
Pejabat Ketua Eksekutif
Unit Komunikasi Korporat
Unit Undang-undang
Unit Integriti
Secretarial Unit
Bahagian Pendaftaran, Pelesenan Dan Penguatkuasaan
Post Market & Enforcement Division
Policy & Strategic Planning Division
International and Industry Affairs Division
Unit Pengurusan Dan Perkhidmatan
Soalan Lazim
Single License Policy Implementation
Pendaftaran, Pelesenan & Penguatkuasaan
Labelling of Medical Devices
Technical Evaluation
Hubungi
Borang Aduan Pelanggan
Direktori Kakitangan
Dokumen
Perundangan
Surat Pekeliling
Dokumen Panduan
Garis panduan
Standard
General Directions
Strategic Plan
Persembahan Slide
Infographic
Organizational Anti Corruption Plan (OACP) MDA 2022 - 2026
Buletin MDA
Press Release
Media Coverage (Newspaper Cutting)
Laporan Tahunan
Customer Satisfaction Survey
Customer Satisfaction Survey Result
Laporan Kajian Kepuasan Pelanggan
Cari
fas fa-search
Laman Utama
Alert
Filters
Penapis Tajuk
Papar #
5
10
15
20
25
30
50
100
Semua
Filter
Tajuk
Dikunjungi
FIELD CORRECTIVE ACTION (FCA) LISTING FOR AUGUST 2022
Dikunjungi: 5810
FIELD CORRECTIVE ACTION (FCA) LISTING FOR JULY 2022
Dikunjungi: 5375
FIELD CORRECTIVE ACTION (FCA) LISTING FOR JUNE 2022
Dikunjungi: 5925
FIELD CORRECTIVE ACTION (FCA) LISTING FOR MAY 2022
Dikunjungi: 5278
FIELD CORRECTIVE ACTION (FCA) LISTING FOR APRIL 2022
Dikunjungi: 5337
FIELD CORRECTIVE ACTION (FCA) LISTING FOR MARCH 2022
Dikunjungi: 5138
December 2021 : Notification of Initiation of FSCA (MY-FSN-CPS-2020-091) - version 8 Elecsys CA 19-9 : Non-reproducible elevated results with certain reagent lots on cobas e 801.
Dikunjungi: 6213
December 2021 : FCA Notification 2021-003M _Olympus Evis Exera II Duodenovideoscope TJF-Q180V : Supplemental material for inspection.
Dikunjungi: 4322
December 2021 : Field Correction Action Report - DELFIA® Xpress_R2021004 : Potential for decreased analyte measurement with DELFIA® Xpress hAFP, Free hCGß, PAPP-A, and hCG kits
Dikunjungi: 7010
December 2021 : [TC2021-192] [Follow Up: Urgent Product Correction] [Availability of Application Software Version 5.13.4 Modification (MOD) 58 & 0.5M NaOH Usage Guidelines for ORTHO VISIONR and ORTHO VISIONR Max Analyzer]
Dikunjungi: 4232
1
2
3
4
5
6
7
8
9
10
Halaman 4 dari 16
Utama
Pengenalan
Latar Belakang
Visi, Misi & Nilai Teras
Objektif
Carta Organisasi
Kod Etika dan Tatakelakuan
Board of Directors
Top Management Team of MDA
Malaysian Leadership
Former CEO of MDA
Bahagian
Pejabat Ketua Eksekutif
Unit Komunikasi Korporat
Unit Undang-undang
Unit Integriti
Secretarial Unit
Bahagian Pendaftaran, Pelesenan Dan Penguatkuasaan
Post Market & Enforcement Division
Policy & Strategic Planning Division
International and Industry Affairs Division
Unit Pengurusan Dan Perkhidmatan
Soalan Lazim
Single License Policy Implementation
Pendaftaran, Pelesenan & Penguatkuasaan
Labelling of Medical Devices
Technical Evaluation
Hubungi
Borang Aduan Pelanggan
Direktori Kakitangan
Dokumen
Perundangan
Surat Pekeliling
Dokumen Panduan
Garis panduan
Standard
General Directions
Strategic Plan
Persembahan Slide
Infographic
Organizational Anti Corruption Plan (OACP) MDA 2022 - 2026
Buletin MDA
Press Release
Media Coverage (Newspaper Cutting)
Laporan Tahunan
Customer Satisfaction Survey
Customer Satisfaction Survey Result
Laporan Kajian Kepuasan Pelanggan
×